Skip to main content
SpringerLink
Log in

Inflammatory and Locally Advanced Breast Cancer

  • Chapter
  • First Online:
Management of Breast Diseases

  • 1362 Accesses

Abstract

Despite the advances in early detection and treatment of breast cancer, a significant proportion of patients still present with locally advanced breast cancer (LABC). These advanced tumors include patients with stage IIB disease (T3N0) and stage IIIA to IIIC disease and are characterized by high relapse rates and poor prognosis. Multimodality management, which includes preoperative systemic therapy followed by surgery and radiation therapy, has had a tremendous impact on the outcome of patients presenting with LABC. Inflammatory breast cancer (IBC) is a particularly aggressive subtype of LABC, which progresses rapidly and is characterized by the presence of edema and erythema of the skin. This chapter reviews the epidemiology, staging, diagnosis, prognostic factors, molecular markers, and treatment approaches for these malignancies. IBC, although included in the definition of LABC, will have separate annotations due to its distinct clinical presentation and aggressive behavior.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Seidman H, Gelb SK, Silverberg E, LaVerda N, Lubera JA. Survival experience in the breast cancer detection demonstration project. CA Cancer J Clin. 1987;37(5):258–90.

    Article  CAS  PubMed  Google Scholar 

  2. Eniu A, Carlson RW, Aziz Z, Bines J, Hortobagyi GN, Bese NS, et al. Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J. 2006;12(Suppl 1):S38–53.

    Article  PubMed  Google Scholar 

  3. Lee MC, Newman LA. Management of patients with locally advanced breast cancer. Surg Clin N Am. 2007;87(2):379–98, ix.

    Google Scholar 

  4. http://www.facs.org/cancer/publicncdb.html [Internet]. 2013 [cited 16 June 2016].

  5. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966–75.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005;22:9–23.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Soliman AS, Banerjee M, Lo AC, Ismail K, Hablas A, Seifeldin IA, et al. High proportion of inflammatory breast cancer in the population-based Cancer Registry of Gharbiah, Egypt. Breast J. 2009;15(4):432–4.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Schairer C, Soliman AS, Omar S, Khaled H, Eissa S, Ayed FB, et al. Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. Cancer Med. 2013;2(2):178–84.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Boussen H, Bouzaiene H, Ben Hassouna J, Gamoudi A, Benna F, Rahal K. Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol. 2008;35(1):17–24.

    Google Scholar 

  10. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 1998;16(12):3731–5.

    Article  CAS  Google Scholar 

  11. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007;110(7):1436–44.

    Article  PubMed  Google Scholar 

  12. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, et al. Trends for inflammatory breast cancer: is survival improving? Oncologist. 2007;12(8):904–12.

    Article  PubMed  Google Scholar 

  13. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, et al. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015.

    Google Scholar 

  14. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2003;21(12):2254–9.

    Article  Google Scholar 

  15. Nadeem R, Chagla LS, Harris O, Desmond S, Thind R, Flavin A, et al. Tumour localisation with a metal coil before the administration of neo-adjuvant chemotherapy. Breast. 2005;14(5):403–7.

    Article  CAS  PubMed  Google Scholar 

  16. Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, et al. Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. Oncologist. 2011;16(6):772–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. National Comprehensive Cancer Network. NCCN guidelines, version 2.2016, invasive breast cancer 2016 [BINV-14]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

  18. Haagensen CD. Diseases of the female breast. Trans N Engl Obstet Gynecol Soc. 1956;10:141–56.

    CAS  PubMed  Google Scholar 

  19. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351–75.

    Article  PubMed  Google Scholar 

  20. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J clin Oncol (Official Journal of the American Society of Clinical Oncology). 1992;10(6):1014–24.

    Article  CAS  Google Scholar 

  21. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2002;20(17):3628–36.

    Article  Google Scholar 

  22. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008;109(3):417–26.

    Article  CAS  PubMed  Google Scholar 

  23. National Comprehensive Cancer Network. NCCN guidelines, version 2.2016, invasive breast cancer 2016 [BINV-K]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

  24. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1978;1(1):53–9.

    Article  PubMed  Google Scholar 

  25. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2008;26(5):778–85.

    Article  Google Scholar 

  26. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188–94.

    Article  PubMed  Google Scholar 

  27. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2005;23(25):5983–92.

    Article  CAS  Google Scholar 

  28. von Minckwitz G, Raab G, Caputo A, Schutte M, Hilfrich J, Blohmer JU, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2005;23(12):2676–85.

    Article  CAS  Google Scholar 

  29. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56.

    Article  CAS  Google Scholar 

  30. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2015;33(1):13–21.

    Article  CAS  Google Scholar 

  31. Rugo HS, Olopade O, DeMichele A, van’t Veer L, Buxton M, Hylton N, et al., editors. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIAL. The 36th annual San Antonio breast cancer symposium, San Antonio, TX, 10–14 Dec 2013.

    Google Scholar 

  32. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100(8):542–51.

    Article  CAS  Google Scholar 

  33. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3(Suppl 2):S69–74.

    Article  PubMed  Google Scholar 

  34. Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). Eur J Cancer. 2013;49(10):2284–93.

    Article  CAS  PubMed  Google Scholar 

  35. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2006;24(12):1831–8.

    Article  CAS  Google Scholar 

  36. Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003;4(5):348–53.

    Article  PubMed  Google Scholar 

  37. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84.

    Article  CAS  PubMed  Google Scholar 

  38. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15(6):640–7.

    Article  CAS  PubMed  Google Scholar 

  39. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res (Official Journal of the American Association for Cancer Research). 2007;13(1):228–33.

    Article  CAS  Google Scholar 

  40. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs. 2011;22(2):128–35.

    Article  CAS  PubMed  Google Scholar 

  41. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  42. Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800.

    Article  CAS  PubMed  Google Scholar 

  43. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO). 2013;24(9):2278–84.

    Article  CAS  Google Scholar 

  44. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135–44.

    Article  CAS  PubMed  Google Scholar 

  45. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40.

    Article  CAS  PubMed  Google Scholar 

  46. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(12):1183–92.

    Article  CAS  PubMed  Google Scholar 

  47. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2016;34(6):542–9.

    Article  CAS  Google Scholar 

  48. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137–46.

    Article  PubMed  CAS  Google Scholar 

  49. Veronesi A, Frustaci S, Tirelli U, Galligioni E, Trovo MG, Crivellari D, et al. Tamoxifen therapy in postmenopausal advanced breast cancer: efficacy at the primary tumor site in 46 evaluable patients. Tumori. 1981;67(3):235–8.

    CAS  PubMed  Google Scholar 

  50. Hoff PM, Valero V, Buzdar AU, Singletary SE, Theriault RL, Booser D, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer. 2000;88(9):2054–60.

    Article  CAS  PubMed  Google Scholar 

  51. Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO). 2012;23(12):3069–74.

    Article  CAS  Google Scholar 

  52. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105(Suppl 1):33–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103.

    Article  CAS  PubMed  Google Scholar 

  54. Gerber B, von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, et al. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Ann Surg Oncol. 2014;21(8):2517–24.

    Article  PubMed  Google Scholar 

  55. von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto) dagger. Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO). 2014;25(12):2363–72.

    Article  Google Scholar 

  56. Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(6):656–66.

    Article  CAS  PubMed  Google Scholar 

  57. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366(4):310–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1037–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Rugo HS, Olopade O, DeMichele A, van’t Veer L, Buxton M, Hylton N, et al. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIAL. The San Antonio breast cancer symposium, San Antonio; 2013.

    Google Scholar 

  60. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO). 2013;24(9):2206–23.

    Article  CAS  Google Scholar 

  61. National Comprehensive Cancer Network. NCCN guidelines, version 2.2016, invasive breast cancer 2016 [BINV-15]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

  62. Estevez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res (Official Journal of the American Association for Cancer Research). 2003;9(2):686–92.

    CAS  Google Scholar 

  63. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 1999;17(11):3412–7.

    Article  CAS  Google Scholar 

  64. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2002;20(6):1456–66.

    Article  CAS  Google Scholar 

  65. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2003;21(22):4165–74.

    Article  CAS  Google Scholar 

  66. Untch M, von Minckwitz G. Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res BCR. 2009;11(2):203.

    Article  PubMed  CAS  Google Scholar 

  67. Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2007;25(19):2678–84.

    Article  CAS  Google Scholar 

  68. Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Leheurteur M, et al. Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer. Oncologist. 2007;12(4):390–6.

    Article  CAS  PubMed  Google Scholar 

  69. Bozzetti F, Saccozzi R, De Lena M, Salvadori B. Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol. 1981;18(4):355–61.

    Article  CAS  PubMed  Google Scholar 

  70. Shenkier T, Weir L, Levine M, Olivotto I, Whelan T, Reyno L, et al. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ. 2004;170(6):983–94.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Lee BJ, Tannenbaum NE. Inflammatory carcinoma of the breast. Surg Gynecol Obstet. 1924;39:580–95.

    Google Scholar 

  72. Atkins HL, Horrigan WD. Treatment of locally advanced carcinoma of the breast with roentgen therapy and simple mastectomy. Am J Roentgenol Radium Ther Nucl Med. 1961;85:860–4.

    CAS  PubMed  Google Scholar 

  73. Toonkel LM, Fix I, Jacobson LH, Bamberg N, Wallach CB. Locally advanced breast carcinoma: results with combined regional therapy. Int J Radiat Oncol Biol Phys. 1986;12(9):1583–7.

    Article  CAS  PubMed  Google Scholar 

  74. Perez CA, Graham ML, Taylor ME, Levy JF, Mortimer JE, Philpott GW, et al. Management of locally advanced carcinoma of the breast. I Noninflammatory. Cancer. 1994;74(1 Suppl):453–65.

    Article  CAS  PubMed  Google Scholar 

  75. Bauer RL, Busch E, Levine E, Edge SB. Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy. Ann Surg Oncol. 1995;2(4):288–94.

    Article  CAS  PubMed  Google Scholar 

  76. Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

    Article  CAS  Google Scholar 

  77. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at MD Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40(4):321–9.

    Article  CAS  PubMed  Google Scholar 

  78. Singletary SE, Ames FC, Buzdar AU. Management of inflammatory breast cancer. World J Surg. 1994;18(1):87–92.

    Article  CAS  PubMed  Google Scholar 

  79. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995;4(4):715–34.

    CAS  PubMed  Google Scholar 

  80. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001;92(7):1775–82.

    Article  CAS  PubMed  Google Scholar 

  81. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the MD Anderson Cancer Center experience. Clin Breast Cancer. 2004;4(6):415–9.

    Article  CAS  PubMed  Google Scholar 

  82. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

    Article  CAS  PubMed  Google Scholar 

  83. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.

    Article  CAS  PubMed  Google Scholar 

  84. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2008;26(7):1066–72.

    Article  CAS  Google Scholar 

  85. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2010;28(20):3248–55.

    Article  CAS  Google Scholar 

  86. Arun B, Slack R, Gehan E, Spitzer T, Meehan KR. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999;85(1):93–9.

    Article  CAS  PubMed  Google Scholar 

  87. Adkins D, Brown R, Trinkaus K, Maziarz R, Luedke S, Freytes C, et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 1999;17(7):2006–14.

    Article  CAS  Google Scholar 

  88. Schwartzberg L, Weaver C, Lewkow L, McAneny B, Zhen B, Birch R, et al. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow Transplant. 1999;24(9):981–7.

    Article  CAS  PubMed  Google Scholar 

  89. Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2004;22(10):1839–48.

    Article  Google Scholar 

  90. Goncalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, et al. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO). 2015;26(8):1692–7.

    Article  CAS  Google Scholar 

  91. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res (Official Journal of the American Association for Cancer Research). 2004;10(23):7965–71.

    Article  Google Scholar 

  92. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2006;24(5):769–77.

    Article  CAS  Google Scholar 

  93. Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M, et al. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res (Official Journal of the American Association for Cancer Research). 2007;13(19):5862–8.

    Article  CAS  Google Scholar 

  94. Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2003;21(13):2492–9.

    Article  CAS  Google Scholar 

  95. Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, et al. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat. 2013;141(3):429–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Matsuda N, Wang X, Krishnamurthy S, Alvarez RH, Willey JS, Lim B, et al., editors. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer. American Society of Clinical Oncology; 2016.

    Google Scholar 

  97. Fouad TM, Kogawa T, Reuben JM, Ueno NT. The role of inflammation in inflammatory breast cancer. Adv Exp Med Biol. 2014;816:53–73.

    Article  CAS  PubMed  Google Scholar 

  98. Haagensen CD, Stout AP. Carcinoma of the breast. II-criteria of operability. Ann Surg. 1943;118(6):1032–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Baclesse F. Five-year results in 431 breast cancers treated solely by roentgen rays. Ann Surg. 1965;161:103–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Zucali R, Uslenghi C, Kenda R, Bonadonna G. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer. 1976;37(3):1422–31.

    Article  CAS  PubMed  Google Scholar 

  101. Harris JR, Sawicka J, Gelman R, Hellman S. Management of locally advanced carcinoma of the breast by primary radiation therapy. Int J Radiat Oncol Biol Phys. 1983;9(3):345–9.

    Article  CAS  PubMed  Google Scholar 

  102. Sheldon T, Hayes DF, Cady B, Parker L, Osteen R, Silver B, et al. Primary radiation therapy for locally advanced breast cancer. Cancer. 1987;60(6):1219–25.

    Article  CAS  PubMed  Google Scholar 

  103. Fletcher GH, Montague ED. Radical irradiation of advanced breast cancer. Am J Roentgenol Radium Ther Nucl Med. 1965;93:573–84.

    CAS  PubMed  Google Scholar 

  104. Spanos WJ Jr, Montague ED, Fletcher GH. Late complications of radiation only for advanced breast cancer. Int J Radiat Oncol Biol Phys. 1980;6(11):1473–6.

    Article  PubMed  Google Scholar 

  105. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2004;22(23):4691–9.

    Article  Google Scholar 

  106. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer. 1992;69(11):2849–52.

    Article  CAS  PubMed  Google Scholar 

  107. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001;182(6):601–8.

    Article  CAS  PubMed  Google Scholar 

  108. Calais G, Descamps P, Chapet S, Turgeon V, Reynaud-Bougnoux A, Lemarie E, et al. Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers. Int J Radiat Oncol Biol Phys. 1993;26(1):37–42.

    Article  CAS  PubMed  Google Scholar 

  109. Conte PF, Alama A, Bertelli G, Canavese G, Carnino F, Catturich A, et al. Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results. Int J Cancer. 1987;40(4):490–4.

    Article  CAS  PubMed  Google Scholar 

  110. Hery M, Namer M, Moro M, Boublil JL, LaLanne CM. Conservative treatment (chemotherapy/radiotherapy) of locally advanced breast cancer. Cancer. 1986;57(9):1744–9.

    Article  CAS  PubMed  Google Scholar 

  111. Perloff M, Lesnick GJ. Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg. 1982;117(7):879–81.

    Article  CAS  PubMed  Google Scholar 

  112. Touboul E, Lefranc JP, Blondon J, Ozsahin M, Mauban S, Schwartz LH, et al. Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. Radiother Oncol (Journal of the European Society for Therapeutic Radiology and Oncology). 1992;25(3):167–75.

    Article  CAS  Google Scholar 

  113. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82(19):1539–45.

    Article  CAS  PubMed  Google Scholar 

  114. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 1994;73(2):362–9.

    Article  CAS  PubMed  Google Scholar 

  115. Powles TJ, Hickish TF, Makris A, Ashley SE, O’Brien ME, Tidy VA, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 1995;13(3):547–52.

    Article  CAS  Google Scholar 

  116. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO). 1999;10(1):47–52.

    Google Scholar 

  117. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Giuliano A, et al. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin. 2002;52(5):277–300.

    Article  PubMed  Google Scholar 

  118. Scarth H, Cantin J, Levine M. Steering Committee on Clinical Practice Guidelines for the C, Treatment of Breast C. Clinical practice guidelines for the care and treatment of breast cancer: mastectomy or lumpectomy? The choice of operation for clinical stages I and II breast cancer (summary of the 2002 update). CMAJ. 2002;167(2):154–5.

    PubMed  PubMed Central  Google Scholar 

  119. Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2014;32(13):1365–83.

    Article  Google Scholar 

  120. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg. 2001;25(6):767–72.

    Article  CAS  PubMed  Google Scholar 

  121. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (> or =5 cm) invasive breast cancer. Ann Surg Oncol. 2001;8(9):688–92.

    CAS  PubMed  Google Scholar 

  122. Wong SL, Chao C, Edwards MJ, Tuttle TM, Noyes RD, Carlson DJ, et al. Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg. 2001;67(6):522–6; discussion 7–8.

    Google Scholar 

  123. Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44(5):989–90.

    Article  CAS  PubMed  Google Scholar 

  124. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2002;20(1):17–23.

    Article  CAS  Google Scholar 

  125. Buchholz TA, Strom EA, Perkins GH, McNeese MD. Controversies regarding the use of radiation after mastectomy in breast cancer. Oncologist. 2002;7(6):539–46.

    Article  PubMed  Google Scholar 

  126. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer. 2003;98(6):1150–60.

    Article  PubMed  Google Scholar 

  127. Brun B, Otmezguine Y, Feuilhade F, Julien M, Lebourgeois JP, Calitchi E, et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer. 1988;61(6):1096–103.

    Article  CAS  PubMed  Google Scholar 

  128. Fields JN, Perez CA, Kuske RR, Fineberg BB, Bartlett N. Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys. 1989;17(2):249–55.

    Article  CAS  PubMed  Google Scholar 

  129. Perez CA, Fields JN. Role of radiation therapy for locally advanced and inflammatory carcinoma of the breast. Oncology (Williston Park). 1987;1(1):81–94.

    CAS  Google Scholar 

  130. Attia-Sobol J, Ferriere JP, Cure H, Kwiatkowski F, Achard JL, Verrelle P, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer. 1993;29A(8):1081–8.

    Article  CAS  PubMed  Google Scholar 

  131. Barker JL, Montague ED, Peters LJ. Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer. 1980;45(4):625–9.

    Article  CAS  PubMed  Google Scholar 

  132. Chu AM, Wood WC, Doucette JA. Inflammatory breast carcinoma treated by radical radiotherapy. Cancer. 1980;45(11):2730–7.

    Article  CAS  PubMed  Google Scholar 

  133. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res BCR. 2000;2(6):423–9.

    Article  CAS  PubMed  Google Scholar 

  134. Turpin E, Bieche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, et al. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene. 2002;21(49):7593–7.

    Article  CAS  PubMed  Google Scholar 

  135. Gruber G, Ciriolo M, Altermatt HJ, Aebi S, Berclaz G, Greiner RH. Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer. 2004;109(1):144–8.

    Article  CAS  PubMed  Google Scholar 

  136. Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget. 2015;6(15):13506–19.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat. 2006;95(3):243–55.

    Article  CAS  PubMed  Google Scholar 

  138. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 2004;64(23):8558–65.

    Article  CAS  PubMed  Google Scholar 

  139. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 2005;65(6):2170–8.

    Article  CAS  PubMed  Google Scholar 

  140. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, et al. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res (Official Journal of the American Association for Cancer Research). 2013;19(17):4685–96.

    Article  CAS  Google Scholar 

  142. Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, et al. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat. 2013;138(3):761–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, et al. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res BCR. 2013;15(6):R112.

    Article  PubMed  CAS  Google Scholar 

  144. Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, et al. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol (Official Journal of the United States and Canadian Academy of Pathology, Inc.). 2016;29(4):330–46.

    Google Scholar 

  145. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, et al. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS ONE. 2014;9(1):e83113.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  146. Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, et al. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer. 1994;69(6):1145–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Riou G, Le MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993;85(21):1765–7.

    Article  CAS  PubMed  Google Scholar 

  148. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res (Official Journal of the American Association for Cancer Research). 2004;10(18 Pt 1):6215–21.

    Article  CAS  Google Scholar 

  149. Kleer CG, van Golen KL, Braun T, Merajver SD. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol (Official Journal of the United States and Canadian Academy of Pathology, Inc.). 2001;14(5):458–64.

    Google Scholar 

  150. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001;61(13):5231–41.

    CAS  PubMed  Google Scholar 

  151. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene. 2002;21(22):3631–43.

    Article  CAS  PubMed  Google Scholar 

  152. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001;61(2):445–51.

    CAS  PubMed  Google Scholar 

  153. Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res (Official Journal of the American Association for Cancer Research). 2005;11(21):7637–42.

    Article  CAS  Google Scholar 

  154. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 1997;57(24):5441–5.

    CAS  PubMed  Google Scholar 

  155. Durand B, Gao FB, Raff M. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J. 1997;16(2):306–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Gonzalez-Angulo AM, Guarneri V, Gong Y, Cristofanilli M, Morales-Vasquez F, Sneige N, et al. Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin Breast Cancer. 2006;7(4):326–30.

    Article  CAS  PubMed  Google Scholar 

  157. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res (Official Journal of the American Association for Cancer Research). 1999;5(9):2511–9.

    Google Scholar 

  158. Ridley AJ. The GTP-binding protein Rho. Int J Biochem Cell Biol. 1997;29(11):1225–9.

    Article  CAS  PubMed  Google Scholar 

  159. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000;60(20):5832–8.

    PubMed  Google Scholar 

  160. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia. 2000;2(5):418–25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  161. Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene. 2002;21(20):3172–80.

    Article  CAS  PubMed  Google Scholar 

  162. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res BCR. 2004;6(1):R110–5.

    Article  PubMed  Google Scholar 

  163. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol. 2008;173(2):561–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (Official Journal of the American Association for Cancer Research). 2010;16(1):45–55.

    Article  CAS  Google Scholar 

  165. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2012;30(15):1796–804.

    Article  Google Scholar 

  166. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2004;22(12):2303–12.

    Article  Google Scholar 

  167. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.

    Article  PubMed  Google Scholar 

  168. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2016;34(10):1034–42.

    Article  CAS  Google Scholar 

  169. Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2014;32(34):3883–91.

    Article  Google Scholar 

  170. Mathieu MC, Mazouni C, Kesty NC, Zhang Y, Scott V, Passeron J, et al. Breast Cancer index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO). 2012;23(8):2046–52.

    Article  CAS  Google Scholar 

  171. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2008;26(2):246–52.

    Article  CAS  Google Scholar 

  172. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2011;29(15):1956–62.

    Article  Google Scholar 

  173. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2007;25(28):4414–22.

    Article  Google Scholar 

  174. Jones RL, Salter J, A’Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116(1):53–68.

    Article  CAS  PubMed  Google Scholar 

  175. Sheri A, Smith IE, Johnston SR, A’Hern R, Nerurkar A, Jones RL, et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO). 2015;26(1):75–80.

    Article  CAS  Google Scholar 

  176. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncology (Official Journal of the American Society of Clinical Oncology). 2004;22(20):4067–74.

    Article  CAS  Google Scholar 

  177. Schlichting JA, Soliman AS, Schairer C, Schottenfeld D, Merajver SD. Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008. Breast Cancer Res Treat. 2012;134(3):1257–68.

    Article  PubMed  PubMed Central  Google Scholar 

  178. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011;117(9):1819–26.

    Article  PubMed  Google Scholar 

  179. Panades M, Olivotto IA, Speers CH, Shenkier T, Olivotto TA, Weir L, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2005;23(9):1941–50.

    Article  Google Scholar 

  180. Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2014;32(19):2018–24.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA

    Tamer M. Fouad, Gabriel N. Hortobagyi & Naoto T. Ueno

Authors
  1. Tamer M. Fouad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriel N. Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoto T. Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoto T. Ueno .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Texas Health Science Center, San Antonio, Texas, USA

    Ismail Jatoi

  2. Obstetrics and Gynecology, University Medical Center Schleswig-Holstein, Luebeck, Germany

    Achim Rody

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fouad, T.M., Hortobagyi, G.N., Ueno, N.T. (2016). Inflammatory and Locally Advanced Breast Cancer. In: Jatoi, I., Rody, A. (eds) Management of Breast Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-46356-8_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46356-8_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-46354-4

  • Online ISBN: 978-3-319-46356-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation